logo
Asian shares are mixed and oil prices advance as Israel-Iran crisis escalates

Asian shares are mixed and oil prices advance as Israel-Iran crisis escalates

HONG KONG (AP) — Asian shares were mixed on Monday and oil prices extended gains on worries that escalating Iran-Israel tensions could disrupt the flow of crude around the world.
U.S. benchmark crude oil added 20 cents to $73.18 per barrel. Brent crude, the international standard, gained 95 cents to $75.18 per barrel.
In share trading, Tokyo's Nikkei 225 added 1.3% to 38,307.74, while the Kospi in Seoul gained 0.9% to 2,920.57.
Chinese markets were little changed after data for May showed stronger consumer spending but weaker factory activity and investment. A 6.1% year-on-year jump in retail sales was offset but lower than expected growth in industrial output, which rose 5.8% from a year earlier.
Hong Kong's Hang Seng fell 0.1% to 23,864.20 and the Shanghai Composite Index added less than 0.1% to 3,378.78.
Australia's S&P/ASX 200 fell 0.2% to 8,547.40.
On Friday, oil prices jumped and stocks slumped after Israel's attack on Iranian nuclear and military targets.
The S&P 500 sank 1.1% to 5,976.97. The Dow Jones Industrial Average dropped 1.8% to 42,197.79, and the Nasdaq composite lost 1.3% to 19,406.83.
The strongest action was in the oil market, where the price of a barrel of benchmark U.S. crude and Brent crude, the international standard surged more than 7%.
Iran is one of the world's major producers of oil, though sanctions by Western countries have limited its sales. If a wider war erupts, it could slow the flow of Iran's oil to its customers and keep the price of crude and gasoline higher for everyone worldwide.
Beyond the oil coming from Iran, analysts also pointed to the potential for disruptions in the Strait of Hormuz, a relatively narrow waterway off Iran's coast. Much of the world's oil that's been pulled from the ground moves through it on ships.
Companies that use a lot of fuel as part of their business and need their customers feeling confident enough to travel suffered some of the sharpest losses. Cruise operator Carnival dropped 4.9%. United Airlines sank 4.4%, and Norwegian Cruise Line Holdings fell 5%.
They helped overshadow gains for U.S. oil producers and other companies that could benefit from increased fighting between Israel and Iran.
Exxon Mobil rose 2.2%, and ConocoPhillips gained 2.4% because the leaping price of crude portends bigger profits for them.
Contractors that make weapons and defense equipment also rallied. Lockheed Martin, Northrop Grumman and RTX all rose more than 3%.
The price of gold climbed as investors searched for safer places to park their cash. An ounce of gold added 1.4% on Friday and was holding steady early Monday.
Prices for Treasury bonds will likewise rise when investors are feeling nervous, but Treasury prices fell Friday, which in turn pushed up their yields, in part because of worries that a spike in oil prices could drive inflation higher.
Inflation has remained relatively tame recently, and it's near the Federal Reserve's target of 2%, but worries are high that it could be set to accelerate because of President Donald Trump's tariffs.
A better-than-expected report Friday on sentiment among U.S. consumers also helped drive yields higher. The preliminary report from the University of Michigan said sentiment improved for the first time in six months after Trump put many of his tariffs on pause, while U.S. consumers' expectations for coming inflation eased.
On Wall Street, Adobe fell 5.3% even though the company behind Photoshop reported a stronger profit for the latest quarter than Wall Street expected. Analysts called it a solid performance but said investors may have been looking for some bigger revenue forecasts for the upcoming year.
In currency trading early Monday, the U.S. dollar gained to 144.37 Japanese yen from 144.03 yen. The euro rose to $1.1537 from $1.1533.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The AREA Welcomes P&C Solution as a Member
The AREA Welcomes P&C Solution as a Member

Business Upturn

time24 minutes ago

  • Business Upturn

The AREA Welcomes P&C Solution as a Member

BOSTON, MA, June 16, 2025 (GLOBE NEWSWIRE) — The Augmented Reality for Enterprise Alliance (AREA) today announced that P&C Solution has joined the consortium. Based in South Korea, P&C Solution is a leading XR Solution company of stand-alone, see-through AR glasses and XR simulators designed for enterprise and defense applications. The company's flagship product, Metalense 2, is already deployed in mission-critical use cases across manufacturing, defense, and healthcare industries. By joining AREA, P&C Solution aims to collaborate with global leaders in the AR ecosystem, contribute to technical standards, and expand opportunities for interoperability and integration in industrial environments. 'We are excited to join the AREA and connect with AR innovators worldwide,' said Chiwon Choi, CEO of P&C Solution. 'Through this membership, we hope to share insights from our real-world deployments, stay ahead of emerging trends, and strengthen partnerships that can accelerate enterprise adoption of AR technologies.' 'P&C Solution is a valued new member of the AREA,' said Mark Sage, AREA Executive Director. 'Their experience deploying AR glasses and XR simulators in mission-critical enterprise and defense industries will help us further the adoption of enterprise AR and XR solutions across many industries.' About P&C Solution Since its inception in 2015, P&C Solution has evolved into a leading XR glasses company in Korea. We launched our first XR Glasses in 2018, driven by the development of XR Simulator at an early stage. We have since conducted continuous research and investment, as a consequence of which we launched the XR Glasses business in earnest in 2020. We are currently focusing our R&D efforts on the metaverse platform applicable to XR Glasses. About the AR for Enterprise Alliance (AREA) The AR for Enterprise Alliance (AREA) is the only global membership-funded alliance helping to accelerate the adoption of enterprise AR by supporting the growth of a comprehensive ecosystem. The AREA accelerates AR adoption by creating a comprehensive ecosystem for enterprises, providers, and research institutions. AREA is a program of Object Management Group® (OMG®). For more information, visit the AREA website . Object Management Group and OMG are registered trademarks of the Object Management Group. For a listing of all OMG trademarks, visit All other trademarks are the property of their respective owners. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Goldman says 'TINA trade' is alive and well, fueled by 401(k) buying
Goldman says 'TINA trade' is alive and well, fueled by 401(k) buying

CNBC

time31 minutes ago

  • CNBC

Goldman says 'TINA trade' is alive and well, fueled by 401(k) buying

The stock market could get another boost on the strength of the "TINA" trade, according to Goldman Sachs. TINA, which stands for "There Is No Alternative," refers to an idea that takes hold when investors believe there is no viable investment to put their money into outside of one specific asset, usually equities. The bull market following the 2008 financial crisis, when low interest rates made bonds a less attractive option, was one such period when the trade gained steam on Wall Street. Now, David Kostin, chief U.S. equity strategist at Goldman Sachs, said he expects that flows into the stock market from retirement accounts will continue to power the current rally. He wrote that the average allocation to stocks from 401(k) plans has risen, up to 71% in 2022 from 66% in 2013, with a big spike among participants in their 20s, to 90% from 76%. "Retirement accounts will continue to support household demand for equities," Kostin wrote in a Friday note titled: "TINA trade remains alive and well in US retirement accounts." "We estimate contributions to 401(k) plans drive roughly $500 billion of annual equity demand, though some of this demand could be allocated to international equities," Kostin added. The growing importance of 401(k) assets to stock market could help tip it back into record territory. The S & P 500 was last just a little more than 2% off its February peak as stocks looked past trade uncertainty, as well as a recent spike in geopolitical risks abroad in Israel and Iran, to mount an impressive comeback. There are a number of reasons to be confident stocks could go higher. Kostin said investor sentiment remains depressed, with the firm's own internal indicator remaining in negative territory, in spite of the recent rally. And, demand for equities from households, which the strategist said directly own 38% of the U.S. equity market, remains resilient. That could mean households can continue to support the stock market later this year, so long as the macroeconomic picture continues to hold. "Outflows from equities occur after household balance sheets weaken, unemployment rises, or short-term interest rates increase. Currently, the US labor market remains solid, household balance sheets are healthy, and the Fed is on hold," Kostin said. He added: "As a result, we continue to expect that US households will buy $425 billion of equities this year."

Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston

Yahoo

time31 minutes ago

  • Yahoo

Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston

Ramat Gan, Israel, June 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that Dr. Sari Fishman, Vice President of Business Development, will present an update on the Company's ongoing Phase IIa study in pancreatic cancer during partnering meetings at the 2025 BIO International Convention, taking place June 16–19 in Boston, MA (link). The Phase IIa clinical trial is open-label study evaluating Namodenoson in patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one prior line of therapy. The study is assessing the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson, administered orally at a dose of 25 mg twice daily in continuous 28-day cycles. Approximately 20 evaluable patients are expected to be enrolled. The trial is led by Prof. Salomon Stemmer, a prominent Oncologist and Key Opinion Leader at the Davidoff Center, Rabin Medical Center, Israel. Namodenoson has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. 'We are pleased to report that 50% of the planned patient cohort has already been enrolled and that Namodenoson has demonstrated a favourable safety profile,' stated Prof. Salomon Stemmer. 'There is a critical unmet need for safe and effective treatment options for patients with advanced pancreatic cancer who have exhausted standard therapies. This study gives us the opportunity to advance a novel therapeutic approach for this challenging disease, stated Dr. Sari Fishman, VP of Business Development at Can-Fite.' Can-Fite looks forward to engaging with potential partners and collaborators at BIO 2025 as it continues to progress its clinical pipeline. About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: Forward-Looking Statements This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are 'forward looking statements'. Forward-looking statements can be identified by the use of forward-looking words such as 'believe,' 'expect,' 'intend,' 'plan,' 'may,' 'should' or 'anticipate' or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the 'Risk Factors' section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Can-Fite BioPharma Motti Farbstein info@ +972-3-9241114Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store